Acute respiratory failure is one of the critical conditions with an increased mortality. In order to reverse lung injury and reduce the mortality rate, several lung replacement therapies have been developed, including the extracorporeal membrane oxygenation, the intravascular oxygenator and carbon dioxide removal device, the intravenous membrane oxygenator and the thoracic artificial lung. This article aims to present the properties, indications and advantages of these devices.
INTRODUCTION
Acute respiratory failure is one of the critical conditions that endangers patients' lives and hence is associated with an increased mortality. In recent years, people have been endeavoring to explore new approaches for the effective treatment of this critical condition in the hope of reversing lung injury and reducing mortality. (1) Currently, several lung replacement therapies are in use, including the extracorporeal membrane oxygenation (ECMO), the intravascular oxygenator and carbon dioxide (CO2) removal device (IVOX), the intravenous membrane oxygenator (IMO) and the thoracic artificial lung (TAL). The oxygenator is the central component of the cardiopulmonary bypass (CPB) or ECMO circuit. The oxygenators provide gas exchange by contact between blood and the gas phase, either with hollow fibers or a folded silicone membrane. (2) An oxygenrich gas mixture is passed through the oxygenator in an opposite direction to blood flow, promoting oxygen diffusion into the blood. (3) This article will briefly present the clinical application of the devices as well as patients' outcomes.
ECMO
ECMO is a mechanical support system used to aid heart and lung function in patients with severe respiratory or cardiac failure aiming at promoting oxygenation and later also at carbon dioxide removal. The technology is similar to CPB, as used during cardiac surgery, but modified for prolonged use at the bedside in the intensive care unit. The differences between ECMO and CPB are shown in Since 1986 extracorporeal circuits and membrane lungs coated with Carmeda Bioactive Surface (CBAS) for extracorporeal lung assistance (ECLA) have been used in 14 patients suffering from ARDS. The patients were on ECLA for 3-55 days with a survival rate of 43%. However, the major drawback of this device was bleeding due to systemic heparinization. (9) Conrad et al. (10) The limitations of ECMO include the requirement for a large and complex blood pump and oxygenator system, the necessity for a surgical procedure for cannulation, the need for systemic anticoagulation, labor intensive implementation, the exceedingly high cost, and a high rate of complications, including bleeding and infection, protein absorption, and platelet adhesion on the surface of the oxygenator membrane. As a result of these limitations, ECMO has become limited for neonatal respiratory failure.
IVOX
Intravenous oxygenation represents a potential respiratory support modality for patients with acute respiratory failure or with acute respiratory exacerbations. The first IVOX, capable of removing 30% of CO2, was invented by Mortensen and Berry in the late 1980's. (18) The IVOX is surgically deployed into the inferior or superior vena cava via a femoral or jugular venotomy, by which gas exchange occurs through the hollow fibers driven by a vacuum pump. (19) There is no extracorporeal circulation of blood. Gas exchange is accomplished as the patient's blood flows through the hollow fibers via inlet and outlet gas conduits for oxygen infusion and CO2 elimination. (20) Clinical experience confirms the safety and simplicity of IVOX, but the mean gas-transfer values represent only 25% of basal requirements. (21) Like ECMO, the IVOX system has numerous limitations including a moderate rate of achievable gas exchange, difficulty in device implantation, a relatively high rate of adverse events, and device malfunctions, such as blood-to-gas leaks due to broken hollow fibers. 
IMO
The current IMO device uses a constrained fiber bundle made by wrapping hollow fiber fabric around a concentrically located polyurethane balloon. The constrained fiber bundle is intentionally smaller than vessel lumen size, which allows for shunt flow of blood past the device to reduce flow resistance. (26) Like IVOX, IMO consists of a bundle of manifolded hollow fibers, and is intended for intravenous placement within the superior and inferior vena cava.
(27) An IMO with a design goal of 50% of basal oxygen and CO2 exchange requirements has been successfully used for treatment of end-stage ARDS. However, it was considered that IVOX and IMO are surface-limited and may provide inadequate gas exchange. (28)
TAL
TALs are an alternative device for bridging patients with respiratory failure to lung transplantation. TALs are attached to the pulmonary circulation, and thus their blood flow is provided by the right ventricle. Current TALs possess blood flow impedances greater than the natural lungs, resulting in low cardiac output when implanted in series with the natural lung or in parallel under exercise conditions. (29) A compliant TAL has been developed for acute respiratory failure or as a bridge to transplantation. The device uses microporous, hollow fiber bundles. The bundle is placed within thermoformed polyethylene terephthalate glucose modified housing with a gross volume of 800 cm3. The development goal was to increase TAL compliance, lower TAL impedance, and improve right ventricular function during use. Prototypes were tested in vitro and in vivo in eight pigs between 67 and 79 kg to determine hemodynamic and gas transfer properties. Device resistance was 1.9 and 1.8 mmHg/L/min) at a flow rate of 4 L/ min in vitro and in vivo, respectively. Approximately 75% of the resistance was at the inlet and outlet. The in vivo TAL oxygen and CO2 transfer rates were 188 and 186 mL/min, respectively. protecting blood components, reducing energy loss and decreasing the infective opportunity. IVOX is free of blood priming, maintenance becomes simple, and the costs are significantly decreased. Pumpfree TAL is now in the process of manufacture. An ideal implantable artificial lung should be flexible, with good gas exchange function and good biological compatibility. Modifications on structure and physical and chemical stability of the medical membranes, arrangements of hollow fibers and prevention of membranous pollution are being undertaken to enhance the properties of the artificial devices. Further research should be concentrated on the improvement of its properties including gas exchange, blood compatibility, hemodynamic compatibility and configuration of the device.
